| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Whooping Cough | 15 | 2023 | 60 | 5.660 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 11 | 2023 | 35 | 4.620 |
Why?
|
| Vaccination | 18 | 2025 | 962 | 3.030 |
Why?
|
| Diphtheria | 4 | 2023 | 15 | 2.320 |
Why?
|
| Immunization | 7 | 2014 | 308 | 1.860 |
Why?
|
| Tetanus | 4 | 2020 | 21 | 1.780 |
Why?
|
| Immunity, Maternally-Acquired | 6 | 2013 | 35 | 1.750 |
Why?
|
| Health Knowledge, Attitudes, Practice | 9 | 2024 | 855 | 1.590 |
Why?
|
| Influenza Vaccines | 3 | 2024 | 481 | 1.300 |
Why?
|
| Vaccines | 6 | 2023 | 366 | 1.200 |
Why?
|
| Antibodies, Bacterial | 5 | 2023 | 390 | 1.130 |
Why?
|
| Papillomavirus Vaccines | 3 | 2023 | 94 | 1.070 |
Why?
|
| Pertussis Toxin | 3 | 2023 | 28 | 1.040 |
Why?
|
| Pregnancy | 21 | 2024 | 7225 | 1.030 |
Why?
|
| Hepatitis B | 3 | 2015 | 161 | 1.020 |
Why?
|
| Hepatitis B Vaccines | 3 | 2015 | 42 | 0.980 |
Why?
|
| Patient Acceptance of Health Care | 7 | 2023 | 426 | 0.960 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2021 | 456 | 0.950 |
Why?
|
| Infant, Newborn | 23 | 2021 | 8272 | 0.900 |
Why?
|
| Papillomavirus Infections | 3 | 2023 | 296 | 0.890 |
Why?
|
| Hepatitis B virus | 2 | 2015 | 130 | 0.880 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 2 | 2023 | 70 | 0.880 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2023 | 345 | 0.870 |
Why?
|
| Pertussis Vaccine | 4 | 2023 | 25 | 0.840 |
Why?
|
| Influenza in Birds | 1 | 2023 | 27 | 0.840 |
Why?
|
| Fluconazole | 3 | 2009 | 48 | 0.840 |
Why?
|
| Transplant Recipients | 2 | 2015 | 217 | 0.830 |
Why?
|
| Influenza A Virus, H7N9 Subtype | 1 | 2023 | 29 | 0.820 |
Why?
|
| Candidiasis | 3 | 2009 | 129 | 0.770 |
Why?
|
| Influenza, Human | 2 | 2024 | 662 | 0.770 |
Why?
|
| Infant, Extremely Low Birth Weight | 3 | 2012 | 38 | 0.740 |
Why?
|
| Health Personnel | 3 | 2015 | 510 | 0.710 |
Why?
|
| Infectious Disease Transmission, Vertical | 4 | 2021 | 243 | 0.680 |
Why?
|
| Immunization Programs | 2 | 2011 | 63 | 0.650 |
Why?
|
| Humans | 69 | 2025 | 125466 | 0.640 |
Why?
|
| Antiviral Agents | 1 | 2024 | 767 | 0.620 |
Why?
|
| Parents | 6 | 2024 | 1024 | 0.610 |
Why?
|
| Female | 42 | 2025 | 66904 | 0.590 |
Why?
|
| Staphylococcal Infections | 3 | 2012 | 562 | 0.590 |
Why?
|
| Adult | 30 | 2025 | 29642 | 0.570 |
Why?
|
| Meningococcal Infections | 4 | 2008 | 19 | 0.560 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2009 | 118 | 0.550 |
Why?
|
| Antifungal Agents | 4 | 2018 | 291 | 0.550 |
Why?
|
| Texas | 11 | 2015 | 3583 | 0.540 |
Why?
|
| Decision Making | 4 | 2015 | 657 | 0.540 |
Why?
|
| Infant | 18 | 2024 | 12601 | 0.540 |
Why?
|
| Intensive Care Units, Neonatal | 5 | 2012 | 316 | 0.530 |
Why?
|
| Adolescent | 26 | 2023 | 19448 | 0.520 |
Why?
|
| Liver Transplantation | 2 | 2015 | 1043 | 0.520 |
Why?
|
| Bacteremia | 3 | 2012 | 407 | 0.500 |
Why?
|
| Postpartum Period | 4 | 2014 | 216 | 0.490 |
Why?
|
| Child | 22 | 2025 | 24607 | 0.480 |
Why?
|
| Young Adult | 15 | 2023 | 9086 | 0.470 |
Why?
|
| Coagulase | 2 | 2012 | 23 | 0.450 |
Why?
|
| Staphylococcus | 2 | 2012 | 69 | 0.440 |
Why?
|
| Streptococcal Infections | 2 | 2022 | 241 | 0.400 |
Why?
|
| Behavior Therapy | 1 | 2014 | 256 | 0.390 |
Why?
|
| Equipment Contamination | 1 | 2012 | 37 | 0.380 |
Why?
|
| Culture Media | 1 | 2012 | 181 | 0.370 |
Why?
|
| Viral Load | 2 | 2024 | 388 | 0.370 |
Why?
|
| Infant, Low Birth Weight | 1 | 2012 | 167 | 0.360 |
Why?
|
| Immunogenicity, Vaccine | 2 | 2022 | 106 | 0.360 |
Why?
|
| Catheterization, Central Venous | 1 | 2012 | 130 | 0.350 |
Why?
|
| Virus Diseases | 1 | 2013 | 280 | 0.340 |
Why?
|
| Bacterial Infections | 1 | 2013 | 307 | 0.340 |
Why?
|
| Meningococcal Vaccines | 2 | 2012 | 30 | 0.330 |
Why?
|
| Male | 29 | 2025 | 61637 | 0.310 |
Why?
|
| Cross Infection | 1 | 2012 | 326 | 0.310 |
Why?
|
| Meningitis, Haemophilus | 1 | 2007 | 34 | 0.290 |
Why?
|
| Middle Aged | 15 | 2025 | 26833 | 0.290 |
Why?
|
| Candida albicans | 1 | 2008 | 76 | 0.280 |
Why?
|
| Family Health | 1 | 2008 | 259 | 0.280 |
Why?
|
| Mycoses | 1 | 2008 | 118 | 0.270 |
Why?
|
| Communication | 1 | 2011 | 515 | 0.270 |
Why?
|
| Hepatitis C | 2 | 2001 | 367 | 0.270 |
Why?
|
| Child, Preschool | 7 | 2024 | 14143 | 0.250 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2025 | 1119 | 0.250 |
Why?
|
| United States | 8 | 2025 | 10926 | 0.240 |
Why?
|
| Measles | 1 | 2025 | 41 | 0.230 |
Why?
|
| Caregivers | 2 | 2024 | 578 | 0.230 |
Why?
|
| Virulence Factors, Bordetella | 1 | 2004 | 23 | 0.230 |
Why?
|
| Fimbriae Proteins | 1 | 2004 | 20 | 0.230 |
Why?
|
| Bordetella pertussis | 1 | 2004 | 16 | 0.230 |
Why?
|
| Hemagglutinins | 1 | 2004 | 23 | 0.230 |
Why?
|
| Methicillin Resistance | 1 | 2004 | 118 | 0.220 |
Why?
|
| Adhesins, Bacterial | 1 | 2004 | 75 | 0.220 |
Why?
|
| Child, Hospitalized | 1 | 2024 | 74 | 0.220 |
Why?
|
| Nasopharynx | 1 | 2024 | 80 | 0.220 |
Why?
|
| Research Design | 2 | 2025 | 694 | 0.220 |
Why?
|
| Breast Feeding | 1 | 2024 | 221 | 0.200 |
Why?
|
| Gestational Age | 3 | 2018 | 1169 | 0.200 |
Why?
|
| Frontal Sinusitis | 1 | 2002 | 4 | 0.200 |
Why?
|
| Antibodies, Viral | 3 | 2023 | 1153 | 0.200 |
Why?
|
| Lymphadenitis | 1 | 2022 | 26 | 0.200 |
Why?
|
| Epidural Abscess | 1 | 2002 | 11 | 0.200 |
Why?
|
| Incidence | 6 | 2021 | 3136 | 0.200 |
Why?
|
| Kinetics | 2 | 2020 | 1333 | 0.200 |
Why?
|
| Infant, Premature, Diseases | 1 | 2004 | 245 | 0.190 |
Why?
|
| Papillomaviridae | 1 | 2022 | 145 | 0.180 |
Why?
|
| Staphylococcus aureus | 1 | 2004 | 462 | 0.180 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2018 | 120 | 0.180 |
Why?
|
| Infant, Very Low Birth Weight | 3 | 2009 | 173 | 0.170 |
Why?
|
| Pregnant Women | 1 | 2021 | 143 | 0.170 |
Why?
|
| Vaccines, Acellular | 1 | 2020 | 5 | 0.170 |
Why?
|
| Risk Factors | 5 | 2015 | 10301 | 0.170 |
Why?
|
| Sepsis | 1 | 2004 | 484 | 0.170 |
Why?
|
| England | 1 | 2020 | 60 | 0.170 |
Why?
|
| Immunity, Innate | 1 | 2022 | 372 | 0.170 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2015 | 51 | 0.160 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 3433 | 0.160 |
Why?
|
| Ethics, Medical | 1 | 2022 | 396 | 0.160 |
Why?
|
| Ireland | 4 | 2003 | 28 | 0.150 |
Why?
|
| Trichosporonosis | 1 | 2018 | 8 | 0.150 |
Why?
|
| Invasive Fungal Infections | 1 | 2018 | 13 | 0.150 |
Why?
|
| Opportunistic Infections | 1 | 2018 | 79 | 0.150 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 320 | 0.140 |
Why?
|
| Streptococcus agalactiae | 2 | 2022 | 99 | 0.140 |
Why?
|
| Mothers | 1 | 2020 | 356 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 824 | 0.140 |
Why?
|
| Logistic Models | 2 | 2015 | 1808 | 0.130 |
Why?
|
| Single-Blind Method | 3 | 2021 | 241 | 0.130 |
Why?
|
| Prenatal Diagnosis | 1 | 2001 | 600 | 0.130 |
Why?
|
| Cohort Studies | 4 | 2008 | 4843 | 0.130 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 294 | 0.130 |
Why?
|
| Exanthema | 1 | 2017 | 71 | 0.130 |
Why?
|
| Immunoglobulin G | 2 | 2012 | 779 | 0.130 |
Why?
|
| Fluticasone-Salmeterol Drug Combination | 1 | 2015 | 8 | 0.120 |
Why?
|
| Cushing Syndrome | 1 | 2015 | 15 | 0.120 |
Why?
|
| Budesonide | 1 | 2015 | 18 | 0.120 |
Why?
|
| Itraconazole | 1 | 2015 | 25 | 0.120 |
Why?
|
| Histoplasma | 1 | 2015 | 31 | 0.120 |
Why?
|
| Protein-Losing Enteropathies | 1 | 2015 | 19 | 0.120 |
Why?
|
| Bronchiectasis | 1 | 2015 | 22 | 0.120 |
Why?
|
| Culture | 1 | 2015 | 68 | 0.120 |
Why?
|
| Histoplasmosis | 1 | 2015 | 48 | 0.120 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2015 | 106 | 0.120 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2014 | 15 | 0.110 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 237 | 0.110 |
Why?
|
| Skin | 1 | 2017 | 521 | 0.110 |
Why?
|
| Vaccines, Combined | 1 | 2023 | 39 | 0.110 |
Why?
|
| Urban Population | 1 | 2015 | 228 | 0.110 |
Why?
|
| Time Factors | 2 | 2015 | 6323 | 0.110 |
Why?
|
| Antibodies | 1 | 2015 | 374 | 0.100 |
Why?
|
| Health Care Surveys | 1 | 2013 | 283 | 0.100 |
Why?
|
| Case-Control Studies | 1 | 2020 | 3310 | 0.100 |
Why?
|
| Multivariate Analysis | 2 | 2008 | 1430 | 0.100 |
Why?
|
| Clinical Protocols | 1 | 2023 | 240 | 0.100 |
Why?
|
| Haemophilus Vaccines | 1 | 2012 | 30 | 0.100 |
Why?
|
| Streptococcal Vaccines | 1 | 2012 | 17 | 0.100 |
Why?
|
| Tetanus Toxoid | 1 | 2012 | 45 | 0.100 |
Why?
|
| Double-Blind Method | 3 | 2022 | 1635 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2018 | 6174 | 0.090 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 774 | 0.090 |
Why?
|
| Data Collection | 1 | 2013 | 381 | 0.090 |
Why?
|
| Aged | 6 | 2024 | 19747 | 0.090 |
Why?
|
| Patient Acuity | 2 | 2021 | 66 | 0.090 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 1900 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 446 | 0.090 |
Why?
|
| Pneumococcal Vaccines | 1 | 2012 | 169 | 0.090 |
Why?
|
| Health Promotion | 1 | 2014 | 390 | 0.090 |
Why?
|
| Professional-Patient Relations | 1 | 2011 | 84 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 3743 | 0.090 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 5174 | 0.090 |
Why?
|
| Research | 1 | 2012 | 262 | 0.090 |
Why?
|
| Developing Countries | 1 | 2012 | 271 | 0.080 |
Why?
|
| Needs Assessment | 1 | 2011 | 175 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2012 | 16362 | 0.080 |
Why?
|
| Antibodies, Neutralizing | 2 | 2022 | 469 | 0.080 |
Why?
|
| Conjunctivitis, Bacterial | 1 | 2008 | 5 | 0.070 |
Why?
|
| Thyroglossal Cyst | 1 | 2008 | 4 | 0.070 |
Why?
|
| Recurrence | 1 | 2012 | 1394 | 0.070 |
Why?
|
| Age Factors | 1 | 2015 | 2828 | 0.070 |
Why?
|
| Prevalence | 1 | 2015 | 2469 | 0.070 |
Why?
|
| Hospitals | 1 | 2011 | 399 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2022 | 12305 | 0.070 |
Why?
|
| Liver | 1 | 2015 | 1749 | 0.070 |
Why?
|
| Neoplasms | 1 | 2022 | 2800 | 0.070 |
Why?
|
| Probability | 1 | 2008 | 318 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 1097 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2023 | 2812 | 0.070 |
Why?
|
| Abscess | 1 | 2008 | 138 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 2913 | 0.070 |
Why?
|
| Tennessee | 1 | 2006 | 27 | 0.060 |
Why?
|
| Maternal Age | 1 | 2006 | 134 | 0.060 |
Why?
|
| Measles Vaccine | 1 | 2025 | 11 | 0.060 |
Why?
|
| Pandemics | 2 | 2023 | 1113 | 0.060 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2008 | 365 | 0.060 |
Why?
|
| Neisseria meningitidis, Serogroup B | 1 | 2005 | 7 | 0.060 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2008 | 798 | 0.060 |
Why?
|
| Infection Control | 1 | 2006 | 156 | 0.060 |
Why?
|
| Drug Resistance, Multiple | 1 | 2004 | 48 | 0.060 |
Why?
|
| Vaccines, Conjugate | 1 | 2005 | 78 | 0.060 |
Why?
|
| Gentamicins | 1 | 2004 | 94 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 3 | 2008 | 2429 | 0.060 |
Why?
|
| Catheters, Indwelling | 1 | 2004 | 153 | 0.050 |
Why?
|
| Information Seeking Behavior | 1 | 2023 | 15 | 0.050 |
Why?
|
| Fetal Blood | 1 | 2004 | 175 | 0.050 |
Why?
|
| Survival Rate | 1 | 2008 | 2050 | 0.050 |
Why?
|
| Age of Onset | 1 | 2004 | 601 | 0.050 |
Why?
|
| Hypoxia | 1 | 2004 | 248 | 0.050 |
Why?
|
| Hypotension | 1 | 2004 | 186 | 0.050 |
Why?
|
| Vancomycin | 1 | 2004 | 217 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 275 | 0.050 |
Why?
|
| Demography | 1 | 2023 | 239 | 0.050 |
Why?
|
| Patient Selection | 1 | 2006 | 697 | 0.050 |
Why?
|
| Cellulitis | 1 | 2022 | 63 | 0.050 |
Why?
|
| Animals | 1 | 2023 | 34309 | 0.050 |
Why?
|
| Serotyping | 1 | 2002 | 178 | 0.050 |
Why?
|
| Craniotomy | 1 | 2002 | 109 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 65 | 0.050 |
Why?
|
| Mexico | 1 | 2021 | 182 | 0.050 |
Why?
|
| Immunization, Secondary | 1 | 2021 | 104 | 0.040 |
Why?
|
| Carrier State | 1 | 2001 | 76 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2022 | 174 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2003 | 818 | 0.040 |
Why?
|
| Zidovudine | 1 | 2000 | 23 | 0.040 |
Why?
|
| Lamivudine | 1 | 2000 | 25 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2000 | 122 | 0.040 |
Why?
|
| HIV Protease Inhibitors | 1 | 2000 | 48 | 0.040 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2000 | 36 | 0.040 |
Why?
|
| Syndrome | 1 | 2022 | 1122 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2001 | 586 | 0.040 |
Why?
|
| Infant, Premature | 1 | 2004 | 833 | 0.040 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 187 | 0.040 |
Why?
|
| Health Policy | 1 | 2001 | 214 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2008 | 3440 | 0.040 |
Why?
|
| Voriconazole | 1 | 2018 | 34 | 0.040 |
Why?
|
| Lipopeptides | 1 | 2018 | 33 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 1173 | 0.040 |
Why?
|
| Delivery, Obstetric | 1 | 2001 | 253 | 0.040 |
Why?
|
| Amphotericin B | 1 | 2018 | 90 | 0.040 |
Why?
|
| Echinocandins | 1 | 2018 | 44 | 0.040 |
Why?
|
| Cytokines | 1 | 2003 | 1288 | 0.040 |
Why?
|
| Blueberry Plants | 1 | 2017 | 6 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2000 | 322 | 0.030 |
Why?
|
| Neutropenia | 1 | 2018 | 199 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2001 | 1399 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 617 | 0.030 |
Why?
|
| HIV-1 | 1 | 2000 | 464 | 0.030 |
Why?
|
| Chimerism | 1 | 2015 | 28 | 0.030 |
Why?
|
| Mass Screening | 1 | 2001 | 785 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2015 | 129 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2015 | 255 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 2093 | 0.030 |
Why?
|
| Phenotype | 1 | 2003 | 4269 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2014 | 266 | 0.030 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 520 | 0.030 |
Why?
|
| Weight Gain | 1 | 2015 | 400 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2023 | 6559 | 0.020 |
Why?
|
| Pedigree | 1 | 2015 | 1609 | 0.020 |
Why?
|
| Child Development | 1 | 2014 | 268 | 0.020 |
Why?
|
| Neisseria meningitidis | 1 | 2008 | 19 | 0.020 |
Why?
|
| Cefotaxime | 1 | 2008 | 35 | 0.020 |
Why?
|
| HIV Infections | 1 | 2000 | 1896 | 0.020 |
Why?
|
| Sialoglycoproteins | 1 | 2003 | 48 | 0.010 |
Why?
|
| Minisatellite Repeats | 1 | 2003 | 42 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2003 | 145 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2003 | 142 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2003 | 54 | 0.010 |
Why?
|
| DNA Primers | 1 | 2003 | 657 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2003 | 174 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2003 | 725 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2003 | 421 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 682 | 0.010 |
Why?
|
| Nelfinavir | 1 | 2000 | 4 | 0.010 |
Why?
|
| Indinavir | 1 | 2000 | 5 | 0.010 |
Why?
|
| Saquinavir | 1 | 2000 | 5 | 0.010 |
Why?
|
| Nevirapine | 1 | 2000 | 15 | 0.010 |
Why?
|
| Ritonavir | 1 | 2000 | 46 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2003 | 2184 | 0.010 |
Why?
|
| Genotype | 1 | 2003 | 2569 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2000 | 595 | 0.010 |
Why?
|